Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
US10328066B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10328066-B2 |
| Application number | US-201615755140-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2016 |
| Priority date | Aug 28, 2015 |
| Publication date | Jun 25, 2019 |
| Grant date | Jun 25, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a colorectal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising: (a) a compound having the structure of the formula (I) or a pharmaceutically acceptable salt thereof, (b) a compound having the structure of Formula (II) or a pharmaceutically acceptable salt thereof, and (c) an antimetabolite antineoplastic agent 5-fluorouracil or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1 , wherein the cancer is characterized by one or more of BRAF mutation, KRAS mutation, CDK4 mutation, CDK6 mutation, CDK4 overexpression, CDK6 overexpression, PIK3CA mutation, and PIK3CA overexpression.
Assignees
Inventors
Classifications
Purines, e.g. adenine · CPC title
condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title
Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos} · CPC title
Antineoplastic agents · CPC title
- A61K31/4439Primary
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10328066B2 cover?
- The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing …
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4439. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).